749928-99-2Relevant academic research and scientific papers
Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5, 7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5, 6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor
Li, Hui,Tatlock, John,Linton, Angelica,Gonzalez, Javier,Jewell, Tanya,Patel, Leena,Ludlum, Sarah,Drowns, Matthew,Rahavendran, Sadayappan V.,Skor, Heather,Hunter, Robert,Shi, Stephanie T.,Herlihy, Koleen J.,Parge, Hans,Hickey, Michael,Yu, Xiu,Chau, Fannie,Nonomiya, Jim,Lewis, Cristina
supporting information; experimental part, p. 1255 - 1258 (2009/12/26)
The HCV RNA-dependent RNA polymerase has emerged as one of the key targets for novel anti-HCV therapy development. Herein, we report the optimization of the dihydropyrone series inhibitors to improve compound aqueous solubility and reduce CYP2D6 inhibitio
INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
-
Page 122, (2008/06/13)
The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).
